Background:Liposarcoma (LPS) is one of the most frequent histotypes of soft tissue sarcoma (STS). Eribulin is a cytotoxic agent that has improved overall survival in patients with advanced LPS. Additionally, preclinical and clinical evidence suggests its influence on vascularization and cellular differentiation. Based on these data, we developed this study to investigate non-mitotic effects of eribulin in patients with advanced LPS.Methods:In this prospective monocentric observational study, we included patients with advanced LPS eligible to receive eribulin. An assessment with dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and a biopsy were planned before treatment and after four cycles of eribulin. DCE-MRI scans were elaborated to obtain perfusion and permeability maps.Results:From September 2019 to January 2024, 11 patients were enrolled. Among them, 8/11 (73%) had successful pre- and post-treatment assessment. At the time of the analysis, 8/11 (73%) patients had disease progression and 4 (36%) had died, median progression-free survival (mPFS) was 3.3 months, and median overall survival (mOS) was 8.7 months. Among the evaluable patients, DCE-MRI perfusion decreased after eribulin treatment in patients with disease control (partial response or stable disease), while perfusion values increased in patients with progressive disease (PD). No significant change in permeability was found. Post-treatment histological changes were seen nearly in all patients, with decreased cellularity the most common change (50%), followed by vascularization modifications (20%).Conclusions:Eribulin appears to exhibit non-mitotic activity involving both vascularization and cell differentiation in LPS patients. Further studies are needed to better define these effects.
背景：脂肪肉瘤（LPS）是软组织肉瘤（STS）中最常见的组织学类型之一。艾日布林是一种细胞毒性药物，可改善晚期LPS患者的总生存期。此外，临床前和临床证据表明其对血管化和细胞分化具有影响。基于这些数据，我们开展了本研究以探讨艾日布林在晚期LPS患者中的非有丝分裂效应。 方法：在这项前瞻性单中心观察性研究中，我们纳入了符合艾日布林治疗条件的晚期LPS患者。计划在治疗前及完成四个周期艾日布林治疗后，分别进行动态对比增强磁共振成像（DCE-MRI）评估和组织活检。通过处理DCE-MRI扫描数据获得灌注和渗透性图谱。 结果：2019年9月至2024年1月期间，共纳入11例患者。其中8/11例（73%）成功完成了治疗前后评估。截至分析时，8/11例（73%）患者出现疾病进展，4例（36%）死亡，中位无进展生存期（mPFS）为3.3个月，中位总生存期（mOS）为8.7个月。在可评估患者中，疾病控制（部分缓解或疾病稳定）患者的DCE-MRI灌注值在艾日布林治疗后下降，而疾病进展（PD）患者的灌注值升高。未发现渗透性发生显著变化。几乎所有患者均观察到治疗后组织学改变，其中细胞密度降低是最常见的变化（50%），其次是血管化改变（20%）。 结论：艾日布林在LPS患者中似乎表现出涉及血管化和细胞分化的非有丝分裂活性。需要进一步研究以更明确地界定这些效应。
肿瘤(癌症)患者之家